Y-mAbs Therapeutics Inc.

This stock has a reasonable momentum. Y-mAbs Therapeutics Inc. is not a good growth stock. Y-mAbs Therapeutics Inc. is a mediocre stock to choose.
Log in to see more information.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody...
YMAB Fundamental Data by TradingView

News

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Reiterated by Cantor Fitzgerald
Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Reiterated by Cantor Fitzgerald

Ticker Report Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report)s stock had its "overweight" rating restated by equities researchers at Cantor Fitzgerald in a note issued to investors on Monday, Benzinga...\n more…

Y-mAbs Therapeutics (NASDAQ:YMAB) Receives "Overweight" Rating from Cantor Fitzgerald
Y-mAbs Therapeutics (NASDAQ:YMAB) Receives "Overweight" Rating from Cantor Fitzgerald

Zolmax Cantor Fitzgerald reiterated their overweight rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB - Free Report) in a research report released on Monday, Benzinga reports. The brokerage currently...\n more…

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from Analysts
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from Analysts

Ticker Report Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm...\n more…

Y-mAbs Therapeutics announces new data on naxitamab, GD2-SADA
Y-mAbs Therapeutics announces new data on naxitamab, GD2-SADA

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Globe Newswire NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs ) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...\n more…

Institutional investors may overlook Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent US$57m market cap drop as long-term gains remain positive
Institutional investors may overlook Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent US$57m market cap drop as long-term gains remain positive

Simply Wall St Key Insights Institutions' substantial holdings in Y-mAbs Therapeutics implies that they have significant influence...\n more…